Heartflow, a California-based leader in AI-powered coronary CT angiography (CCTA) evaluations, has filed for an initial public offering (IPO) on Nasdaq under the ticker HTFL, aiming to raise $100 million.
The company’s AI platform, Heartflow One, includes key tools like Roadmap Analysis, FFRCT Analysis, and Plaque Analysis, which have supported management of over 400,000 heart patients globally. Heartflow’s move follows major policy milestones boosting adoption and reimbursement, including expanded Medicare coverage for coronary plaque evaluation tools and a new CPT code set to take effect in 2026.
In November 2024, CMS nearly doubled Medicare reimbursements for CCTA procedures, raising the payment rate from $175 to $357.13, enhancing clinical and economic incentives for Heartflow’s offerings.
Recent data presented at SCCT 2025 show Heartflow’s Plaque Analysis changes patient management by enabling personalized treatment based on plaque burden and risk stratification.
Heartflow nearly went public in 2021 via a merger with Longview Acquisition Corp. II but withdrew due to market conditions. The current IPO filing signals renewed confidence amid a growing market for AI-driven cardiac diagnostics.
Follow MEDWIRE.AI for the latest in cardiovascular AI innovation and market developments.
